Discovery of a Novel Series of Thienopyrimidine as Highly Potent and Selective PI3K Inhibitors
摘要:
Inhibition of the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway provides a promising new approach for cancer therapy. Through a rational design, a novel series of thienopyrimidine was discovered as highly potent and selective PI3K inhibitors. These thienopyrimidine derivatives were demonstrated to bear nanomolar PI3K alpha inhibitory potency with over 100-fold selectivity against mTOR kinase. The lead compounds 6g and 6k showed good developability profiles in cell-based proliferation and ADME assays. In this communication, their design, synthesis, structure activity relationship, selectivity, and some developability properties are described.
The invention relates to new naphthyridine derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
This paper describes the different strategies devised and applied to overcome the selectivity issues in the syntheses of 6,7-disubstituted-1H-quinolin-4-one, 7-substituted-1H-1,6-naphthyridin-4-one and 6-substituted-1H-1,7-naphthyridin-4-one derivatives. They allowed us to improve the overall yields and the scating-up feasibility. Several examples illustrate these strategies with their advantages and drawbacks. (C) 2008 Elsevier Ltd. All rights reserved.
Pyridopyrazine and naphthyridine derivatives for the treatment of cancer
申请人:Astex Therapeutics Limited
公开号:EP2861584B1
公开(公告)日:2020-02-19
NEW COMPOUNDS
申请人:ASTEX THERAPEUTICS LIMITED
公开号:US20150057293A1
公开(公告)日:2015-02-26
The invention relates to new naphthyridine derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
NAPHTHYRIDINE DERIVATIVE COMPOUNDS
申请人:ASTEX THERAPEUTICS LIMITED
公开号:US20160108034A1
公开(公告)日:2016-04-21
The invention relates to new naphthyridine derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.